Connor, Clark & Lunn Investment Management Ltd. Neurocrine Biosciences Inc Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $20 Billion
- Q4 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 63,582 shares of NBIX stock, worth $7.05 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
63,582
Previous 17,186
269.96%
Holding current value
$7.05 Million
Previous $1.98 Million
338.73%
% of portfolio
0.04%
Previous 0.01%
Shares
18 transactions
Others Institutions Holding NBIX
# of Institutions
655Shares Held
96.6MCall Options Held
282KPut Options Held
281K-
Black Rock Inc. New York, NY14.2MShares$1.57 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.12 Billion0.02% of portfolio
-
State Street Corp Boston, MA4.89MShares$542 Million0.03% of portfolio
-
Dodge & Cox San Francisco, CA3.02MShares$334 Million0.26% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.54MShares$281 Million0.06% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $10.6B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...